Research programme: antibody-drug conjugates - Adimab/Mersana Therapeutics

Drug Profile

Research programme: antibody-drug conjugates - Adimab/Mersana Therapeutics

Alternative Names: Fleximer®-ADC - Adimab/Mersana Therapeutics; Trastuzumab-m-Dolaflexin®; Trastuzumab-s-Dolaflexin®; XMT-1535; XMT-1536

Latest Information Update: 06 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adimab; Mersana Therapeutics
  • Class Antineoplastics; Depsipeptides; Drug conjugates; Immunoconjugates
  • Mechanism of Action Immunomodulators; Type IIb sodium-phosphate cotransporter protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Non-small cell lung cancer

Most Recent Events

  • 30 Oct 2017 Additional pharmacodynamics data from a preclinical study in Cancer released by Mersana Therapeutics
  • 30 Oct 2017 US FDA approves IND application for XMT 1536 in Cancer
  • 30 Oct 2017 Mersana Therapeutics plans a phase I trial for XMT 1536 in Cancer in early 2018 (CTP#279524)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top